文档介绍：Jack Cuzick, . Wolfson Institute of Preventive Medicine St Bartholomew’s Medical School London, United Kingdom A Review of Endocrine Treatment for Early Breast Cancer Tamoxifen Results from 15 000 randomised women ~5 years Tamoxifen vs not, split by ER status only: RECURRENCE ER-poor disease ER+ disease ER+ disease ~5 years tamoxifen vs. Not, ER+ only BREAST CANCER MORTALITY ~5 years tamoxifen vs not: MORTALITY ECOG, Scottish & NSABP B-14 ~1,600 aTTom ~7,100 ATLAS ~11,500 Five trials of 10 vs 5 years of tamoxifen 20,000 randomised; follow-up continues J. Ingle, M. Dowsett, J. Cuzick, C. Davies for the Aromatase Inhibitors Overview Group (AIOG) Aromataseinhibitors versus tamoxifenas adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapyand switching strategies. Comparison of Tamoxifenand an AromataseInhibitor: Designs of Cohort 1 and Cohort 2 CP1157143-1 Cohort 2: Comparison after 2-3 years of tamoxifen Tamoxifen AromataseInhibitor Cohort 1: parison as monotherapy 5 yr 2-3 yr 2-3 yr R R 5 yr Trials ATAC BIG 1-98/IBCSG 18-98 Trials GABG/ARNO IES/BIG 2-97 ITA ABCSG VIII Cohort 1: parison of Tamoxifen and an Aromatase Inhibitor (9856 patients) Cohort 1: Recurrence